Press Releases

Institute for OneWorld Health CEO To Speak at World Economic Forum

Nonprofit Pharma Shares Learnings, Vision with Global Leaders

San Francisco, CA - January 23, 2006

Victoria Hale, PhD, founder and CEO of the first nonprofit pharmaceutical company in the U.S., the Institute for OneWorld Health, will share her success and vision as a Schwab Foundation Social Entrepreneur with participants at this year’s World Economic Forum in Davos, Switzerland. Dr. Hale will serve as a discussion leader for a session titled, “Defining Success,” at 12:30 p.m. on Jan. 27. In this role, Dr. Hale will guide a group of Young Global Leaders and Social Entrepreneurs in a dialogue about their visions of success.

In addition, Dr. Hale will join other World Economic Forum attendees at various sessions that day, including, “Changing the Rules,” focused on the ascent of women leaders in organizations and, “Not Gone, but Almost Forgotten,” focused on diseases that primarily afflict people in developing countries.

“This is a pivotal time in pharmaceutical science,” stated Dr. Hale. “We have the knowledge and technology to literally save millions of lives. The World Economic Forum provides us with the opportunity to engage some of the brightest minds in the world to address the roadblocks to developing affordable drugs for people most in need. The nonprofit pharmaceutical company is one model to address this problem, but we must continue to challenge existing methods to explore and develop other entrepreneurial approaches and solutions.”

Following the World Economic Forum, Dr. Hale will attend the “Malaria and Neglected Tropical Diseases Quick-Impact Initiative.” It is part of the UN Millennium Development Goals, at the Nobel Forum, Karolinska Institutet in Stockholm, Sweden on Jan. 30 and 31. This meeting includes a press conference on Jan. 30 at 6:15 p.m. OneWorld Health manages a malaria drug and vaccine program.

About The Institute for OneWorld Health

The Institute for OneWorld Health, the first U.S. nonprofit pharmaceutical company, develops safe, effective, affordable new medicines for people with diseases of the developing world, including visceral leishmaniasis, malaria, diarrhea, and Chagas disease. OneWorld Health applies its entrepreneurial business model with a staff of experienced pharmaceutical scientists that identifies promising leads and drives development from pre-clinical studies to clinical trials through regulatory approval. The Institute for OneWorld Health, headquartered in San Francisco, Calif., is a tax-exempt 501(c) (3) U.S. corporation (http://www.oneworldhealth.org/) ). Media resources are available at http://www.oneworldhealth.org/media/index.php/ .

###

RSS Feed